Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 vs Docetaxel in Advanced Breast Cancer
NCT07805135Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2026
- Primary completion
- Jun 2028
01
Overview
Phase 3, randomised, open-label trial of albumin-bound docetaxel in breast cancer (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Progression-Free Survival at 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
albumin-bound docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07805135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07805135.